-
| ISIN | US38942Q2021 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Market Cap | 21M |
|---|---|
| Beta | 1.11 |
| PE Ratio | None |
| Target Price | 16 |
| Dividend Yield | None |
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CALC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025